News
ACHL
0.8037
+3.04%
0.0237
Weekly Report: what happened at ACHL last week (0422-0426)?
Weekly Report · 6d ago
Weekly Report: what happened at ACHL last week (0415-0419)?
Weekly Report · 04/22 09:10
Weekly Report: what happened at ACHL last week (0408-0412)?
Weekly Report · 04/15 09:09
Weekly Report: what happened at ACHL last week (0401-0405)?
Weekly Report · 04/08 09:10
Piper downgrades Achilles to neutral, cites latest data
Healthcare Piper downgrades Achilles to neutral, cites latest data from its precision T cell therapy. Achilles released data from the CHIRON and THETIS studies on Thursday. Piper lowered its price target for the stock to $2 from $8, citing the latest data.
Seeking Alpha · 04/05 14:44
Achilles Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/05 10:47
Achilles Therapeutics Price Target Cut to $6.00/Share From $11.00 by Chardan Capital
Dow Jones · 04/05 10:47
Achilles Therapeutics Cut to Neutral From Overweight by Piper Sandler
Dow Jones · 04/05 10:43
Achilles Therapeutics Price Target Cut to $2.00/Share From $8.00 by Piper Sandler
Dow Jones · 04/05 10:43
Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $6
Benzinga · 04/05 10:38
Piper Sandler Downgrades Achilles Therapeutics to Neutral, Lowers Price Target to $2
Benzinga · 04/05 10:32
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
The Dow Jones index fell more than 200 points on Thursday. U.S. Stocks turned lower toward the end of trading. The Dow traded down 0.59% to 38,894.58 while the NASDAQ fell 0.10%. Health care shares rose by just 0.1% on Thursday after RPM International reported third-quarter results. Asian markets closed higher on Thursday; European shares closed mostly higher.
Benzinga · 04/04 18:39
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday. The company issued strong preliminary first-quarter net sales guidance. TC Biopharm (Holdings) Plc shares climbed 130.1% in the mid-day session.
Benzinga · 04/04 17:21
BRNS, UPC and KWE among mid-day movers
On the Move BRNS, UPC and KWE among mid-day movers. Allurion Technologies (ALUR) and Candel Therapeutics (CADL) Gainers: Allurion and HWH. Losers: eFFECTOR and AXT.
Seeking Alpha · 04/04 17:06
Achilles Therapeutics GAAP EPS of -$0.46 misses by $0.32
Seeking Alpha · 04/04 16:31
12 Health Care Stocks Moving In Thursday's Intraday Session
Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday's regular session. Macrogenics ( NASDAQ:MGNX) stock rose 32.55% during the session. Barinthus Biotherapeutics shares increased by 29.55%.
Benzinga · 04/04 16:31
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
U.S. Stocks traded higher midway through trading on Thursday. The Dow traded up 0.49% while the NASDAQ rose 1%. Real estate shares jumped by 1.1% on Thursday; health care shares rose by just 0.01%. ConAgra Brands Inc reported better-than-expected third-quarter financial results.
Benzinga · 04/04 15:58
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
Achilles Therapeutics reported earnings per share of -46 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -14 cents. Achilles Therapeutic is a drug company.
Investorplace · 04/04 15:53
ARCA biopharma, Achilles Therapeutics, MSP Recovery among healthcare movers
Healthcare On the Move ARCA biopharma, Achilles Therapeutics, MSP Recovery among healthcare movers. S&P 500 Health Care Sector +0.45% to 1687.02. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 04/04 14:00
EC, ABAT and BORR among pre-market losers
On the Move EC, ABAT and BORR among pre-market losers. Keyarch Acquisition Corp (KYCH) reports fourth quarter and year-end 2023 financial results and recent business highlights. ABIO, XTIA, CGC, HSDT, ONMD, KYCH and ABAT also lose ground.
Seeking Alpha · 04/04 12:25
More
Webull provides a variety of real-time ACHL stock news. You can receive the latest news about Achilles Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ACHL
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.